ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.
1. A liposomal vesicle comprising:
at least a first lipid bilayer and a second lipid bilayer; and
a plurality of reversible crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein
each crosslinkage of the plurality of reversible crosslinkages comprises boronic ester bonds,
each crosslinkage is formed using a crosslinker,
the crosslinker comprises two terminal ends, and
each terminal end of the two terminal ends comprises a boronate center.
2. The liposomal vesicle of claim 1 , wherein each crosslinkage of the plurality of reversible crosslinkages is reversed in the presence of reactive oxygen species.
3. The liposomal vesicle of claim 1 , wherein the first and second lipid bilayers comprise lipids selected from the group consisting of phospholipids, sphingolipids, glycosphingolipids, saturated glycerides, steroids, synthetic phospholipids, and combinations thereof.
4. The liposomal vesicle of claim 1 , wherein the first and second lipid bilayers comprise one or more components selected from the group consisting of detergents, PEGylated molecules, protein-conjugated molecules, and molecules with aliphatic anchors.
5. The liposomal vesicle of claim 1 , wherein the liposomal vesicle comprises one or more active agents.
6. The liposomal vesicle of claim 5 , wherein the one or more active agents are encapsulated within the vesicle.
7. The liposomal vesicle of claim 6 , wherein the one or more active agents are between the first lipid bilayer and the second lipid bilayer.
8. The liposomal vesicle of claim 6 , wherein the one or more active agents are embedded within the first lipid bilayer, the second lipid bilayer, or both the first lipid bilayer and the second lipid bilayer.
9. The liposomal vesicle of claim 6 , wherein the one or more active agents are located in an inner cavity of the liposomal vesicle.
10. The liposomal vesicle of claim 5 , wherein the one of more active agents are released in the presence of reactive oxygen species.
11. The liposomal vesicle of claim 5 , wherein the active agent is selected from the group consisting of a nucleic acid, a polypeptide, an antibody, a small molecule, and any combination thereof.
12. The liposomal vesicle of claim 1 , wherein the liposomal vesicle has a diameter of 500 to 5,000 nm.
13. The liposomal vesicle of claim 1 , wherein the liposomal vesicle further comprises a targeting molecule.
14. A pharmaceutical composition comprising one or more liposomal vesicles of claim 5 and a pharmaceutically acceptable excipient.
15. The liposomal vesicle of claim 1 , wherein the crosslinker comprises an aryl boronic acid, a phenylboronate, a pyridylboronate, or a cyclohexylboronate.
16. The liposomal vesicle of claim 1 , wherein each crosslinkage comprises two boronic ester bonds.